ZA201007976B - Anti-pirb antibodies - Google Patents

Anti-pirb antibodies

Info

Publication number
ZA201007976B
ZA201007976B ZA2010/07976A ZA201007976A ZA201007976B ZA 201007976 B ZA201007976 B ZA 201007976B ZA 2010/07976 A ZA2010/07976 A ZA 2010/07976A ZA 201007976 A ZA201007976 A ZA 201007976A ZA 201007976 B ZA201007976 B ZA 201007976B
Authority
ZA
South Africa
Prior art keywords
pirb
antibodies
pirb antibodies
Prior art date
Application number
ZA2010/07976A
Other languages
English (en)
Inventor
Jasvinder Atawal
Marc Tessier-Lavigne
Yan Wu
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/208,883 external-priority patent/US20100047232A1/en
Priority claimed from US12/316,130 external-priority patent/US20090232794A1/en
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of ZA201007976B publication Critical patent/ZA201007976B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ZA2010/07976A 2008-05-13 2010-11-08 Anti-pirb antibodies ZA201007976B (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US5294908P 2008-05-13 2008-05-13
US12/208,883 US20100047232A1 (en) 2006-11-14 2008-09-11 Modulators of neuronal regeneration
US12/316,130 US20090232794A1 (en) 2007-12-11 2008-12-09 Modulators of neuronal regeneration
PCT/US2009/043757 WO2009140361A1 (en) 2008-05-13 2009-05-13 ANTI-PirB ANTIBODIES

Publications (1)

Publication Number Publication Date
ZA201007976B true ZA201007976B (en) 2012-02-29

Family

ID=41319035

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2010/07976A ZA201007976B (en) 2008-05-13 2010-11-08 Anti-pirb antibodies

Country Status (15)

Country Link
EP (1) EP2291405A1 (zh)
JP (1) JP2011523359A (zh)
KR (1) KR20110011676A (zh)
CN (1) CN102089327A (zh)
AR (1) AR071777A1 (zh)
AU (1) AU2009246443A1 (zh)
BR (1) BRPI0912769A2 (zh)
CA (1) CA2723430A1 (zh)
IL (1) IL209129A0 (zh)
MX (1) MX2010012299A (zh)
PE (1) PE20091969A1 (zh)
RU (1) RU2010150754A (zh)
TW (1) TW200950808A (zh)
WO (1) WO2009140361A1 (zh)
ZA (1) ZA201007976B (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2525813B1 (en) 2010-01-20 2017-01-04 Merck Sharp & Dohme Corp. Anti-ilt5 antibodies and ilt5-binding antibody fragments
EP2525822B1 (en) 2010-01-20 2017-05-10 Merck Sharp & Dohme Corp. Immunoregulation by anti-ilt5 antibodies and ilt5-binding antibody fragments
ES2870717T3 (es) * 2012-04-17 2021-10-27 Mayo Found Medical Education & Res Anticuerpos humanos y secuencias de unión específicas del mismo para su uso en accidente cerebrovascular e isquemia y condiciones isquémicas
CN103130898B (zh) * 2013-01-28 2014-03-26 中国人民解放军第四军医大学 Tat-lbd-pep融合蛋白及其在治疗中枢神经系统损伤疾病中的应用
AU2018389111A1 (en) 2017-12-22 2020-06-18 Jounce Therapeutics, Inc. Antibodies to LILRB2
JP7411627B2 (ja) 2018-07-09 2024-01-11 ファイヴ プライム セラピューティクス インク Ｉｌｔ４と結合する抗体
CN109439661B (zh) * 2018-10-22 2020-10-23 西安医学院 抑制pirB表达的短发卡shRNA、慢病毒及其应用
CN116589581A (zh) 2020-05-01 2023-08-15 恩格姆生物制药公司 Ilt结合剂和其使用方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1453540A4 (en) * 2001-11-14 2005-06-01 Immunex Corp MODULATION OF THE LIR FUNCTION FOR THE TREATMENT OF RHEUMATOID ARTHRITIS
EP1981522B1 (en) * 2006-01-23 2012-09-12 President and Fellows of Harvard College Compositions and methods for enhancing neuronal plasticity and regeneration

Also Published As

Publication number Publication date
MX2010012299A (es) 2010-12-06
CN102089327A (zh) 2011-06-08
PE20091969A1 (es) 2010-01-15
KR20110011676A (ko) 2011-02-08
EP2291405A1 (en) 2011-03-09
BRPI0912769A2 (pt) 2015-10-13
JP2011523359A (ja) 2011-08-11
AR071777A1 (es) 2010-07-14
AU2009246443A1 (en) 2009-11-19
CA2723430A1 (en) 2009-11-19
WO2009140361A1 (en) 2009-11-19
RU2010150754A (ru) 2012-06-20
TW200950808A (en) 2009-12-16
IL209129A0 (en) 2011-01-31

Similar Documents

Publication Publication Date Title
EP2241578A4 (en) ANTI-CLDN6 ANTIBODIES
ZA201102119B (en) Improved antibody libraies
GB0821100D0 (en) Antibodies
GB0708002D0 (en) Antibodies
IL214996A0 (en) Anti-bcma antibodies
GB0920127D0 (en) Antibodies
GB0909906D0 (en) Antibodies
EP2337798A4 (en) BSA-SPECIFIC ANTIBODIES
HK1136970A1 (zh) 五特異性抗體
SI2200700T1 (sl) Nova protitelesa
EP2377932A4 (en) ANTIBODIES AGAINST SIGLEC-15
EP2138576A4 (en) ANTI-CLAUDIN-4 ANTIBODY
EP2427496A4 (en) ANTI-VEGF-D ANTIBODIES
EP2172483A4 (en) ANTI-MUC17 ANTIBODY
GB0718737D0 (en) Antibodies
ZA201006099B (en) Anti-tyrp1 antibodies
GB0702888D0 (en) Novel Antibodies
IL205073A0 (en) Anti-bst2 antibody
GB0920324D0 (en) Antibodies
HK1170745A1 (zh) 的抗體
ZA201007976B (en) Anti-pirb antibodies
GB0818356D0 (en) Antibodies
EP2304439A4 (en) ANTI-phospho-AKT ANTIBODY
EP2499256A4 (en) ANTI-C-MPL ANTIBODIES
GB2473934A8 (en) Antibody